Beta
Today
Capital & Financial Markets 9 Nov 2026

Toyobo books pharma contract manufacturing impairment, lifts operating profit forecast

Toyobo has recorded an extraordinary impairment loss in the second quarter of the year to March 2027, writing assets in its pharmaceutical contract manufacturing business down to their recoverable amount. It now expects full-year net sales, operating income and ordinary income above previous guidance, but net income attributable to owners of the parent below it. The revision was announced on 9 November 2026.

Why this mattersThe write-down is confined to pharmaceutical contract manufacturing, while higher sales and operating profit guidance indicate the rest of the group is trading ahead of plan.

  • Extraordinary impairment loss recorded in Q2 of the year to March 2027
  • The impairment relates to pharmaceutical contract manufacturing assets
  • Full-year net sales, operating income and ordinary income forecasts raised above previous guidance
  • Full-year net income attributable to owners of the parent now expected below previous guidance
  • Year to March 2026: net sales USD 2,670m (JPY 421,563m), operating income USD 176.7m (JPY 27,906m)
Toyobo
Sources japanir.jp
Relevant to you?

Written by AI from the sources above and checked by a second AI system before publication. No human wrote or edited this story. How it is made.

Updates

  • 2026-11-10 · Edited before publication: The source contradicts itself on the impairment: 'JPY 6.5 billion' in the text but '6.5 hundred million yen' (JPY 650m) in the key figures. Under the grounding rule the amount is left out. The JPY -3,000m figure had no USD conversion and has been replaced. A pharma contract-manufacturing write-down is not a packaging story, so materiality is lowered to 2.